Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.
biomarkers
fibulin-3
mesothelin
mesothelioma
pleural effusion
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
received:
28
09
2023
revised:
30
10
2023
accepted:
07
11
2023
medline:
25
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Pleural mesothelioma (PM) is a type of cancer that is highly related to exposure to asbestos fibers. It shows aggressive behavior, and the current therapeutic approaches are usually insufficient to change the poor prognosis. Moreover, apart from staging and histological classification, there are no validated predictors of its response to treatment or its long-term outcomes. Numerous studies have investigated minimally invasive biomarkers in pleural fluid or blood to aid in earlier diagnosis and prognostic assessment of PM. The most studied marker in pleural effusion is mesothelin, which exhibits good specificity but low sensitivity, especially for non-epithelioid PM. Other biomarkers found in pleural fluid include fibulin-3, hyaluronan, microRNAs, and CYFRA-21.1, which have lower diagnostic capabilities but provide prognostic information and have potential roles as therapeutic targets. Serum is the most investigated matrix for biomarkers of PM. Several serum biomarkers in PM have been studied, with mesothelin, osteopontin, and fibulin-3 being the most often tested. A soluble mesothelin-related peptide (SMRP) is the only FDA-approved biomarker in patients with suspected mesothelioma. With different serum and pleural fluid cut-offs, it provides useful information on the diagnosis, prognosis, follow-up, and response to therapy in epithelioid PM. Panels combining different markers and proteomics technologies show promise in terms of improving clinical performance in the diagnosis and monitoring of mesothelioma patients. However, there is still no evidence that early detection can improve the treatment outcomes of PM patients.
Identifiants
pubmed: 38002620
pii: jcm12227006
doi: 10.3390/jcm12227006
pmc: PMC10672377
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
World J Clin Cases. 2022 Apr 6;10(10):3088-3100
pubmed: 35647131
J Thorac Oncol. 2021 Oct;16(10):1705-1717
pubmed: 34116230
Biomark Res. 2020 May 13;8:15
pubmed: 32435497
Respir Res. 2015 Dec 22;16:153
pubmed: 26695618
Am J Respir Crit Care Med. 2009 May 15;179(10):950-4
pubmed: 19201924
Clin Cancer Res. 2016 Jun 15;22(12):3087-96
pubmed: 26733616
Technol Cancer Res Treat. 2009 Oct;8(5):323-32
pubmed: 19754208
Drug Metab Pers Ther. 2018 Mar 28;33(1):15-32
pubmed: 29537211
Respir Investig. 2013 Jun;51(2):92-7
pubmed: 23790737
Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
Oncotarget. 2017 Jul 11;8(28):46425-46435
pubmed: 28507279
Sci Rep. 2018 Sep 25;8(1):14321
pubmed: 30254313
BMC Cancer. 2010 May 28;10:242
pubmed: 20509881
N Engl J Med. 2012 Oct 11;367(15):1417-27
pubmed: 23050525
Clin Cancer Res. 2011 Mar 1;17(5):1181-9
pubmed: 21177406
Lancet. 2016 Apr 2;387(10026):1405-1414
pubmed: 26719230
J Thorac Dis. 2018 Jan;10(Suppl 2):S353-S359
pubmed: 29507805
Lung Cancer. 2015 Dec;90(3):457-64
pubmed: 26431916
Carcinogenesis. 2008 Aug;29(8):1555-9
pubmed: 18310086
Appl Immunohistochem Mol Morphol. 2020 Jan;28(1):67-73
pubmed: 30640754
Dis Markers. 2019 Feb 12;2019:4183157
pubmed: 30891101
Arch Pathol Lab Med. 2018 Jan;142(1):89-108
pubmed: 28686500
J Thorac Dis. 2015 Jun;7(6):1041-51
pubmed: 26150917
Cancers (Basel). 2022 Feb 18;14(4):
pubmed: 35205798
Clin Chem Lab Med. 2011 Jan;49(1):5-7
pubmed: 21158701
J Clin Oncol. 2010 Jul 10;28(20):3316-22
pubmed: 20498407
J Cell Biochem. 2019 Mar;120(3):3203-3211
pubmed: 30362153
Transl Cancer Res. 2022 Dec;11(12):4434-4440
pubmed: 36644178
Br J Cancer. 2015 Sep 15;113(6):963-9
pubmed: 26263483
Am J Surg Pathol. 1992 Mar;16(3):259-68
pubmed: 1599018
Clin Biochem. 2012 May;45(7-8):575-81
pubmed: 22374169
Lung Cancer. 2018 Oct;124:19-22
pubmed: 30268460
Hum Pathol. 2007 Jan;38(1):1-16
pubmed: 17056092
Dis Markers. 2017;2017:9280170
pubmed: 28321148
Biomedicines. 2021 Aug 13;9(8):
pubmed: 34440210
Diagnostics (Basel). 2021 Oct 29;11(11):
pubmed: 34829362
Lung Cancer. 2021 Apr;154:5-12
pubmed: 33561782
Chest. 2012 Feb;141(2):477-484
pubmed: 21737491
Transl Lung Cancer Res. 2021 Mar;10(3):1557-1570
pubmed: 33889529
Clin Cancer Res. 2007 May 15;13(10):2928-35
pubmed: 17504993
Rev Pneumol Clin. 2018 Dec;74(6):427-435
pubmed: 30293912
Dis Markers. 2013;35(2):119-27
pubmed: 24167356
Oncotarget. 2017 May 17;8(32):53751-53762
pubmed: 28881848
PLoS One. 2011 Apr 01;6(4):e18232
pubmed: 21483773
Anticancer Res. 2017 Mar;37(3):1387-1391
pubmed: 28314308
J Thorac Oncol. 2008 Aug;3(8):851-7
pubmed: 18670302
Thorax. 2014 Oct;69(10):895-902
pubmed: 25037982
Int J Mol Sci. 2022 Mar 03;23(5):
pubmed: 35269947
J Thorac Oncol. 2022 May;17(5):608-622
pubmed: 35026477
Cancer Res. 1993 Jan 15;53(2):388-92
pubmed: 8417831
Anticancer Res. 2013 Dec;33(12):5517-24
pubmed: 24324091
J Thorac Oncol. 2010 Apr;5(4):479-83
pubmed: 20357617
Eur Respir J. 2020 Jun 11;55(6):
pubmed: 32451346
Adv Exp Med Biol. 2022;1374:41-49
pubmed: 34787829
Br J Cancer. 2017 Mar 14;116(6):731-741
pubmed: 28170372
BMC Cancer. 2017 May 30;17(1):386
pubmed: 28558669
Sci Rep. 2019 Aug 12;9(1):11688
pubmed: 31406207
Eur Respir Rev. 2021 Nov 17;30(162):
pubmed: 34789461
Medicine (Baltimore). 2019 Apr;98(14):e14979
pubmed: 30946324
BMC Cancer. 2018 Feb 17;18(1):199
pubmed: 29454314
Transl Cancer Res. 2021 Apr;10(4):1856-1862
pubmed: 35116507
Eur Respir Rev. 2021 Jan 19;30(159):
pubmed: 33472960
Respir Med. 2011 Jan;105(1):137-42
pubmed: 21041073
Biomolecules. 2020 Sep 08;10(9):
pubmed: 32911658
Dis Markers. 2017;2017:3510984
pubmed: 28348450
Anticancer Res. 2019 Sep;39(9):5219-5223
pubmed: 31519636
Oncotarget. 2017 Aug 24;8(44):78193-78207
pubmed: 29100460
Cancer Cell Int. 2022 Feb 3;22(1):60
pubmed: 35114996
PLoS One. 2013 Aug 21;8(8):e72030
pubmed: 23991032
J Clin Oncol. 2012 May 1;30(13):1541-9
pubmed: 22412141
J Thorac Oncol. 2021 Nov;16(11):1925-1935
pubmed: 34242791
Asian Pac J Cancer Prev. 2014;15(1):363-8
pubmed: 24528057
Ann Thorac Surg. 2017 Nov;104(5):1679-1687
pubmed: 28964420
Pharmaceutics. 2023 May 31;15(6):
pubmed: 37376078
BMJ Open. 2014 Feb 24;4(2):e004145
pubmed: 24566531
Arch Biochem Biophys. 2015 Jun 15;576:32-8
pubmed: 25726727
Cytopathology. 2022 Jan;33(1):77-83
pubmed: 34046958
Med Oncol. 2013 Jun;30(2):543
pubmed: 23532816
Cancers (Basel). 2018 Jun 15;10(6):
pubmed: 29914087
BMC Res Notes. 2023 Apr 24;16(1):61
pubmed: 37095543
Cancers (Basel). 2023 Jan 19;15(3):
pubmed: 36765599
Thorax. 2018 Mar;73(Suppl 1):i1-i30
pubmed: 29444986
Dis Markers. 2019 Jul 31;2019:8628612
pubmed: 31481984
Biomark Res. 2019 Aug 23;7:18
pubmed: 31463062
Clin Cancer Res. 2022 Feb 1;28(3):446-451
pubmed: 34462287
Lung Cancer. 2011 Oct;74(1):55-60
pubmed: 21397972
Lung Cancer. 2013 Dec;82(3):491-8
pubmed: 24161718
Ann Oncol. 2022 Feb;33(2):129-142
pubmed: 34861373
Medicina (Kaunas). 2022 Dec 19;58(12):
pubmed: 36557076
PLoS One. 2017 May 4;12(5):e0176680
pubmed: 28472171
Pathology. 2018 Oct;50(6):635-641
pubmed: 30145072
Oncology. 2006;71(1-2):26-31
pubmed: 17344668
J Thorac Oncol. 2011 Nov;6(11):1930-7
pubmed: 21841505
Clin Biochem. 2000 Jul;33(5):405-10
pubmed: 11018693
Oncotarget. 2017 Feb 21;8(8):13030-13038
pubmed: 28103581
Lung. 2016 Jun;194(3):409-17
pubmed: 27032653
Int J Biol Markers. 2010 Jul-Sep;25(3):164-70
pubmed: 20878622
Dis Markers. 2017;2017:5756102
pubmed: 28348451
Front Oncol. 2022 Oct 11;12:1014749
pubmed: 36303838
Biochim Biophys Acta. 2014 May;1844(5):874-83
pubmed: 24361552
J Thorac Oncol. 2019 Mar;14(3):527-539
pubmed: 30408567
Front Oncol. 2020 Feb 07;10:105
pubmed: 32117755
J Clin Pathol. 2013 Oct;66(10):847-53
pubmed: 23814259
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2524-2540
pubmed: 32699075
Mod Pathol. 2003 Mar;16(3):192-7
pubmed: 12640097
Crit Rev Toxicol. 2022 Apr;52(4):317-324
pubmed: 35852497
BMJ Open. 2017 Oct 11;7(10):e017104
pubmed: 29025836
Cancers (Basel). 2021 Aug 04;13(16):
pubmed: 34439085
Am J Respir Crit Care Med. 2010 Mar 15;181(6):620-5
pubmed: 20075387
J Appl Lab Med. 2018 Sep;3(2):166-177
pubmed: 30370398
BMC Cancer. 2023 Jul 26;23(1):698
pubmed: 37495975
J Biol Chem. 2011 Jun 3;286(22):19478-88
pubmed: 21489980
Clin Cancer Res. 2007 Mar 1;13(5):1571-5
pubmed: 17332303
Diagnostics (Basel). 2022 Sep 12;12(9):
pubmed: 36140611
Clin Cancer Res. 2020 Mar 15;26(6):1529
pubmed: 32169964
Mol Ther Nucleic Acids. 2021 Apr 03;24:669-681
pubmed: 33996251
J Thorac Oncol. 2013 Jul;8(7):947-51
pubmed: 23777840
PLoS One. 2019 May 9;14(5):e0216561
pubmed: 31071161
Radiol Oncol. 2020 Mar 7;54(1):86-95
pubmed: 32187018
Asian Pac J Cancer Prev. 2015;16(4):1403-7
pubmed: 25743806
Expert Rev Mol Diagn. 2023 Oct 5;:1-12
pubmed: 37797209
Thorac Cancer. 2021 Jan;12(1):8-12
pubmed: 33225621